PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.02. Howard Marks would check for debt covenant compliance and refinancing risks.
-2.58
Net cash position versus Medical - Pharmaceuticals median net debt of 2.40. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
88.55
Coverage of 88.55 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.90
Current ratio 50-75% of Medical - Pharmaceuticals median of 1.58. Martin Whitman would look for hidden assets or working capital optimization.
0.61%
Intangibles 50-90% of Medical - Pharmaceuticals median of 0.84%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.